Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study …
S Takaki, M Kurosaki, N Mori, K Tsuji, H Ochi… - Investigational New …, 2023 - Springer
This study aimed to describe the real-world efficacy and safety of the combination therapy of
atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma …
atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma …
[HTML][HTML] Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer
J Feliu, A Salud, MJ Safont, C García-Girón… - PLoS …, 2015 - journals.plos.org
Background Studies suggest a relationship between hypertension and outcome in
bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a …
bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a …
[HTML][HTML] Antiangiogenic drug-induced proteinuria as a prognostic factor in metastatic colorectal cancer
DC Moisuc, MV Marinca, B Gafton, T Alexa-Stratulat… - Current …, 2022 - mdpi.com
Treatment with bevacizumab is known to cause adverse events such as proteinuria and
hypertension, amongst others. However, while bevacizumab-induced hypertension has …
hypertension, amongst others. However, while bevacizumab-induced hypertension has …
[HTML][HTML] Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio?(VERSiON UP study)
M Nakamura, T Funakoshi, S Kataoka, T Horimatsu… - BMC cancer, 2022 - Springer
Background Monitoring proteinuria is important for the management of patients with cancer
treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) …
treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) …
Renin–angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis
T Hirai, Y Shuji, M Takiyama, K Hanada… - Cancer Chemotherapy and …, 2019 - Springer
Purpose Occurrence of proteinuria could result in cessation of bevacizumab and
ramucirumab treatments. Renin–angiotensin system (RAS) inhibitors exert a renoprotective …
ramucirumab treatments. Renin–angiotensin system (RAS) inhibitors exert a renoprotective …
[HTML][HTML] Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)
F Kreidieh, J McQuade - … Heart Journal Plus: Cardiology Research and …, 2024 - Elsevier
Novel immune and targeted therapies approved over the past 2 decades have resulted in
dramatic improvements in cancer-specific outcomes for many cancer patients. However …
dramatic improvements in cancer-specific outcomes for many cancer patients. However …
[HTML][HTML] Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: a meta-analysis
X Chen, Y Chen, X Cai, D Zhang, L Fan… - Journal of Cancer …, 2017 - journals.lww.com
Aims: Bevacizumab plus chemotherapy (CT) has been the standard treatment for advanced
colorectal cancer (ACRC) in the last decade. However, whether geriatric patients treated …
colorectal cancer (ACRC) in the last decade. However, whether geriatric patients treated …
Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer
U Varol, I Yildiz, T Salman, B Karabulut… - Tumori …, 2014 - journals.sagepub.com
The identification of clinical, biochemical and molecular markers to predict or monitor the
efficacy of bevacizumab represents a major point in the treatment of patients with metastatic …
efficacy of bevacizumab represents a major point in the treatment of patients with metastatic …
Antiangiogenic Drug-induced Proteinuria as a Predictive Factor in Metastatic Colorectal Cancer (mCRC)
DC Moisuc, MV Marinca, B Gafton, T Alexa-Stratulat… - 2021 - researchsquare.com
Background: Treatment with bevacizumab is known to cause adverse effects such as
proteinuria, hypertension, fistulas which, in addition to chemotherapy-induced toxicity, affect …
proteinuria, hypertension, fistulas which, in addition to chemotherapy-induced toxicity, affect …
Correlation of Bevacizumab-induced Proteinuria with Therapeutic Effects in Patients with Colorectal Cancer
YJ Sa, KD Kim, HL Ahn - Korean Journal of Clinical Pharmacy, 2020 - koreascience.kr
Background: Bevacizumab-induced proteinuria is known to occur when vascular endothelial
cell receptors are blocked, which leads to decreased protein filtration. Although several …
cell receptors are blocked, which leads to decreased protein filtration. Although several …